Treatment of pediatric multiple sclerosis

Neuropediatrics

Volumn 44, Issue 6, 2013, Pages 309-313

  Kornek, Barbara ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

disease modifying therapy; multiple sclerosis; pediatric

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; CHILDHOOD DISEASE; CONSENSUS; CONTRAST ENHANCEMENT; DIARRHEA; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG SAFETY; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; JC VIRUS; LEUKOPENIA; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REVIEW; RISK FACTOR; SIDE EFFECT; STEROID THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

CHILD; HUMANS; MULTIPLE SCLEROSIS; PEDIATRICS;

EID: 84888646044     PISSN: 0174304X     EISSN: 14391899     Source Type: Journal    
DOI: 10.1055/s-0033-1359308     Document Type: Review

References (87)

1. Boiko A., Vorobeychik G., Paty D., Devonshire V., Sadovnick D. University of British Columbia MS Clinic Neurologists Early onset multiple sclerosis: a longitudinal study. Neurology: 2002; 59 7 1006 1010
2. Simone I. L., Carrara D., Tortorella C., et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology: 2002; 59 12 1922 1928
3. Renoux C., Vukusic S., Mikaeloff Y., et al. Adult Neurology Departments KIDMUS Study Group. Natural history of multiple sclerosis with childhood onset. N Engl J Med: 2007; 356 25 2603 2613
4. Venkateswaran S., Banwell B. Pediatric multiple sclerosis. Neurologist: 2010; 16 2 92 105
5. Banwell B., Ghezzi A., Bar-Or A., Mikaeloff Y., Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol: 2007; 6 10 887 902
6. Ruggieri M., Iannetti P., Polizzi A., Pavone L., Grimaldi L. M. Italian Society of Paediatric Neurology Study Group on Childhood Multiple Sclerosis Multiple sclerosis in children under 10 years of age. Neurol Sci: 2004; 25 04 S326 S335
7. Gorman M. P., Healy B. C., Polgar-Turcsanyi M., Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol: 2009; 66 1 54 59
8. Julian L., Serafin D., Charvet L., et al. Network of Pediatric MS Centers of Excellence. Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol: 2013; 28 1 102 107
9. Amato M. P., Goretti B., Ghezzi A., et al. Multiple Sclerosis Study Group of the Italian Neurological Society. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology: 2010; 75 13 1134 1140
10. Banwell B. Treatment of children and adolescents with multiple sclerosis. Expert Rev Neurother: 2005; 5 3 391 401
11. Pohl D., Waubant E., Banwell B., et al. International Pediatric MS Study Group. Treatment of pediatric multiple sclerosis and variants. Neurology: 2007; 68 16 02 S54 S65
12. Ghezzi A., Banwell B., Boyko A., et al. The management of multiple sclerosis in children: a European view. Mult Scler: 2010; 16 10 1258 1267
13. Ghezzi A. Therapeutic strategies in childhood multiple sclerosis. Ther Adv Neurol Disord: 2010; 3 4 217 228
14. Banwell B., Bar-Or A., Giovannoni G., Dale R. C., Tardieu M. Therapies for multiple sclerosis: considerations in the pediatric patient. Nat Rev Neurol: 2011; 7 2 109 122
15. Chitnis T., Tenembaum S., Banwell B., et al. International Pediatric Multiple Sclerosis Study Group. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler: 2012; 18 1 116 127
16. Johnston J., So T. Y. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview. Drugs: 2012; 72 9 1195 1211
17. Chitnis T. Disease-modifying therapy of pediatric multiple sclerosis. Neurotherapeutics: 2013; 10 1 89 96
18. Goodin D. S., Frohman E. M., Garmany G. P. Jr., et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology: 2002; 58 2 169 178
19. Compston A., Coles A. Multiple sclerosis. Lancet: 2002; 359 9313 1221 1231
20. Optic Neuritis Study Group The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology: 1997; 49 5 1404 1413
21. Waldman A. T., Gorman M. P., Rensel M. R., Austin T. E., Hertz D. P., Kuntz N. L.; Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol: 2011; 26 6 675 682
22. Weinshenker B. G., O'Brien P. C., Petterson T. M., et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol: 1999; 46 6 878 886
23. Takahashi I., Sawaishi Y., Takeda O., Enoki M., Takada G. Childhood multiple sclerosis treated with plasmapheresis. Pediatr Neurol: 1997; 17 1 83 87
24. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology: 1993; 43 4 655 661
25. Jacobs L. D., Cookfair D. L., Rudick R. A., et al. The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol: 1996; 39 3 285 294
26. Group P. RISMS. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet: 1998; 352 9139 1498 1504
27. Johnson K. P., Brooks B. R., Cohen J. A., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology: 1995; 45 7 1268 1276
28. Jacobs L. D., Beck R. W., Simon J. H., et al. CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med: 2000; 343 13 898 904
29. Comi G., Filippi M., Barkhof F., et al. Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet: 2001; 357 9268 1576 1582
30. Kappos L., Freedman M. S., Polman C. H., et al. BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet: 2007; 370 9585 389 397
31. Comi G., Martinelli V., Rodegher M., et al. PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet: 2009; 374 9700 1503 1511
32. Filippini G., Del Giovane C., Vacchi L., et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. (Review) Cochrane Database Syst Rev: 2013; 6 CD008933
33. Ebers G. C., Reder A. T., Traboulsee A., et al. Investigators of the 16-Year Long-Term Follow-Up Study. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther: 2009; 31 8 1724 1736
34. Bermel R. A., Weinstock-Guttman B., Bourdette D., Foulds P., You X., Rudick R. A. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler: 2010; 16 5 588 596
35. Kappos L., Traboulsee A., Constantinescu C., et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology: 2006; 67 6 944 953
36. Ford C., Goodman A. D., Johnson K., et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler: 2010; 16 3 342 350
37. Goodin D. S., Ebers G. C., Cutter G., et al. Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. BMJ Open: 2012; 2 6 e001972
38. Mikaeloff Y., Moreau T., Debouverie M., et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr: 2001; 139 3 443 446
39. Waubant E., Hietpas J., Stewart T., et al. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics: 2001; 32 4 211 213
40. Pohl D., Rostasy K., Gärtner J., Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology: 2005; 64 5 888 890
41. Ghezzi A., Amato M. P., Capobianco M., et al. Immunomodulatory Treatment of Early onset MS Group. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler: 2005; 11 4 420 424
42. Ghezzi A., Amato M. P., Capobianco M., et al. Immunomodulatory Treatment of Early-onset MS (ITEMS) Group. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. Neurol Sci: 2007; 28 3 127 132
43. Banwell B., Reder A. T., Krupp L., et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology: 2006; 66 4 472 476
44. Tenembaum S. N., Segura M. J. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology: 2006; 67 3 511 513
45. Mikaeloff Y., Caridade G., Tardieu M., Suissa S.; KIDSEP study group of the French Neuropediatric Society. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol: 2008; 12 3 205 209
46. Tenembaum S. N., Banwell B., Pohl D., et al. REPLAY Study Group. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol: 2013; 28 7 849 856
47. Kornek B., Bernert G., Balassy C., Geldner J., Prayer D., Feucht M. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics: 2003; 34 3 120 126
48. Krupp L. B., Banwell B., Tenembaum S.; International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology: 2007; 68 16 02 S7 S12
49. Krupp L. B., Tardieu M., Amato M. P., et al. International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler: 2013; 19 10 1261 1267
50. Polman C. H., Reingold S. C., Banwell B., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol: 2011; 69 2 292 302
51. Yeh E. A., Waubant E., Krupp L. B., et al. National Network of Pediatric MS Centers of Excellence. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol: 2011; 68 4 437 444
52. Polman C. H., O'Connor P. W., Havrdova E., et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med: 2006; 354 9 899 910
53. Rudick R. A., Stuart W. H., Calabresi P. A., et al. SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med: 2006; 354 9 911 923
54. Huppke P., Stark W., Zürcher C., Huppke B., Brück W., Gärtner J. Natalizumab use in pediatric multiple sclerosis. Arch Neurol: 2008; 65 12 1655 1658
55. Borriello G., Prosperini L., Luchetti A., et al. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol: 2009; 13 76 71
56. Ghezzi A., Pozzilli C., Grimaldi L. M., et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology: 2010; 75 10 912 917
57. Ghezzi A., Pozzilli C., Grimaldi L. ME., et al. Italian MS Study Group. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler: 2013; 19 8 1106 1112
58. Kornek B., Aboul-Enein F., Rostasy K., et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol: 2013; 70 4 469 475
59. Bloomgren G., Richman S., Hotermans C., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med: 2012; 366 20 1870 1880
60. Kappos L., Bates D., Edan G., et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol: 2011; 10 8 745 758
61. Sorensen P. S., Bertolotto A., Edan G., et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler: 2012; 18 2 143 152
62. Bozic C., Richman S., Plavina T. Prevalence of anti-JCV antibodies in MS patients receiving or considering treatment with natalizumab: baseline results of STRATIFY-1. Neurology: 2011; 76 04 A598
63. Trampe A. K., Hemmelmann C., Stroet A., et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology: 2012; 78 22 1736 1742
64. Kappos L., Radue E. W., O'Connor P., et al. FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med: 2010; 362 5 387 401
65. Cohen J. A., Barkhof F., Comi G., et al. TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med: 2010; 362 5 402 415
66. Oh J., O'Connor P. W. Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis. CNS Drugs: 2013; 27 8 591 609
67. FDA Gilenya (fingolimod): drug safety communication-safety review of a reported death after the first dose. 2011;, updated 2012. http://www.fda.gov/ Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm284355. htm
68. Makhani N., Gorman M. P., Branson H. M., Stazzone L., Banwell B. L., Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology: 2009; 72 24 2076 2082
69. Hartung H. P., Gonsette R., König N., et al. Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet: 2002; 360 9350 2018 2025
70. Kornek B., Bernert G., Rostasy K., et al. Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis. Neuropediatrics: 2011; 42 1 7 12
71. Fox R. J., Miller D. H., Phillips J. T., et al. CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med: 2012; 367 12 1087 1097
72. Gold R., Kappos L., Arnold D. L., et al. DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med: 2012; 367 12 1098 1107
73. Ermis U., Wiesmann M., Nolte K., et al. Fumaric acid-associated progressive multifocal leukencephalopathy (PML), treatment and survival in a patient with psoriasis. (published online: September 30, 2011). Kongress der Deutschen Gesellschaft für Neurologie. 2011
74. van Oosten B. W., Killestein J., Barkhof F., Polman C. H., Wattjes M. P. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med: 2013; 368 17 1658 1659
75. O'Connor P., Wolinsky J. S., Confavreux C., et al. TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med: 2011; 365 14 1293 1303
76. Kappos L., ed. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER: a phase III, placebo-controlled study (Presentation 153). ECTRIMS, Lyon, France: 2012
77. Comi G., Jeffery D., Kappos L., et al. ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med: 2012; 366 11 1000 1009
78. Comi G., Vollmer T., Sorensen S., et al. Pooled analyses from the ALLEGRO and BRAVO trials on the safety and tolerability of laquinimod as a multiple sclerosis treatment (P04.132). American Academy of Neurology, New Orleans, USA: 2012
79. Hauser S. L., Waubant E., Arnold D. L., et al. HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med: 2008; 358 7 676 688
80. Carson K. R., Evens A. M., Richey E. A., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood: 2009; 113 20 4834 4840
81. Tzaribachev N., Koetter I., Kuemmerle-Deschner J. B., Schedel J. Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J: 2009; 2 6609
82. Cohen J. A., Coles A. J., Arnold D. L., et al. CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet: 2012; 380 9856 1819 1828
83. Coles A. J., Twyman C. L., Arnold D. L., et al. CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet: 2012; 380 9856 1829 1839
84. Wynn D., Kaufman M., Montalban X., et al. CHOICE investigators. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol: 2010; 9 4 381 390
85. Gold R., Giovannoni G., Selmaj K., et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet: 2013; 381 9884 2167 2175
86. Gorman M. P., Tillema J. M., Ciliax A. M., Guttmann C. R., Chitnis T. Daclizumab use in patients with pediatric multiple sclerosis. Arch Neurol: 2012; 69 1 78 81
87. Menzin J., Caon C., Nichols C., White L. A., Friedman M., Pill M. W. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm: 2013; 19 (1, Suppl A): S24 S40